Skip to main content
Erschienen in: Journal of Experimental & Clinical Cancer Research 1/2022

Open Access 01.12.2022 | Correction

Correction: JMJD2C promotes colorectal cancer metastasis via regulating histone methylation of MALAT1 promoter and enhancing β-catenin signaling pathway

verfasst von: Xinnan Wu, Ruixiao Li, Qing Song, Chengcheng Zhang, Ru Jia, Zhifen Han, Lihong Zhou, Hua Sui, Xuan Liu, Huirong Zhu, Liu Yang, Yan Wang, Qing Ji, Qi Li

Erschienen in: Journal of Experimental & Clinical Cancer Research | Ausgabe 1/2022

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Correction: J Exp Clin Cancer Res 38, 435 (2019)
https://doi.org/10.1186/s13046-019-1439-x
Following publication of the original article [1], errors were identified in Figs. 2, 3, 7 and S1; specifically:
  • Figure 2F: an image for the shRNA/JMJD2C group (72h) was incorrectly used for a representative picture; the correct image is now used; correspondingly, the quantitative graph in Fig. 2G has also been corrected
  • Figure 3B: one set of immunofluorescence pictures for shRNA/NC group were incorrectly used for the representative pictures; the correct images are now used
  • Figure 7: the order of shRNA/NC group and EmptyVector group for c-Myc was accidentally reversed in typesetting, which was inconsistent with the JMJD2C images in Figure 6 and ITGBL1 images in Figure 7; both sets of images have now been transposed to correct the error
  • Figure S1D: an image for Empty Vector group was incorrectly used for a representative picture; the correct image is now used; correspondingly, the quantitative graph in Figure S1E has also been corrected.
The corrections do not have any effect on the final conclusions of the paper.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Correction: JMJD2C promotes colorectal cancer metastasis via regulating histone methylation of MALAT1 promoter and enhancing β-catenin signaling pathway
verfasst von
Xinnan Wu
Ruixiao Li
Qing Song
Chengcheng Zhang
Ru Jia
Zhifen Han
Lihong Zhou
Hua Sui
Xuan Liu
Huirong Zhu
Liu Yang
Yan Wang
Qing Ji
Qi Li
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
Journal of Experimental & Clinical Cancer Research / Ausgabe 1/2022
Elektronische ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-022-02407-0

Weitere Artikel der Ausgabe 1/2022

Journal of Experimental & Clinical Cancer Research 1/2022 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.